Target alternative vaccine safety testing strategies for pertussis toxin

Procedia in Vaccinology

Volumn 5, Issue , 2011, Pages 248-260

  Arciniega, Juan L ^a   Corvette, Laura ^a   Hsu, Henry ^a   Lynn, Freyja ^a   Romani, Theresa ^a   Dobbelaer, Roland ^b  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b Institut Scientifique de Sante Publique   (Belgium)

Author keywords

Pertussis; Testing; Vaccine

Indexed keywords

HISTAMINE; HISTAMINE H1 RECEPTOR; PERTUSSIS TOXIN; PERTUSSIS VACCINE; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ARTICLE; BODY TEMPERATURE; BORDETELLA PERTUSSIS; CHO CELL; DOSE RESPONSE; DRUG ANTIGENICITY; DRUG HYPERSENSITIVITY; DRUG MANUFACTURE; DRUG SAFETY; DRUG SCREENING; DRUG SENSITIZATION; EUROPE; GENE LOCUS; GENETICS; HISTAMINE SENSITIZATION ASSAY; HYPOVOLEMIA; LETHALITY; LEUKOCYTOSIS; MEDICAL LITERATURE; MOUSE; MOUSE STRAIN; NONHUMAN; PERTUSSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUANTITATIVE ASSAY; REPRODUCIBILITY; SEPTIC SHOCK; TOXICITY TESTING; UNITED STATES; VALIDITY;

EID: 84555190312     PISSN: None     EISSN: 1877282X     Source Type: Journal    
DOI: 10.1016/j.provac.2011.10.026     Document Type: Article

References (42)

1. World Health Organization. Pertussis vaccines-WHO position paper. Wkly Epidemiol Rec 2005;80(4):31-39.
2. Heininger U. Update on pertussis in children. Expert Rev Anti Infect Ther 2010, 8(2):163-173.
3. Carbonetti NH. Pertussis toxin and adenylate cyclase toxin: key virulence factors of Bordetella pertussis and cell biology tools. Future Microbiol 2010;5(3):455-69.
4. Asworth L.T., Robinson A., Irons L.I., Morgan D., Isaacs D. Antigens in whooping cough vaccine and antibody levels induced by vaccination of children. Lancet 1983, 2(8355):878-881.
5. Toyota T, Kai Y, Kakizaki M, Sakai A, Goto Y, Yajima M, Ui M. Effects of islet activating protein (IAP) on blood glucose and plasma insulin in healthy volunteers (phase 1 studies). Tohoku J Exp Med 1980;130(2):105-16.
6. Hendriksen C., Arciniega J.L., Bruckner L., Chevalier M., Coppens E., Descamps J., et al. The consistency approach for the quality control of vaccines. Biologicals 2008, 36(1):73-77.
7. Parfentjev I.A., Goodline A. Histamine shock in mice sensitized with Hemophilus pertussis vaccine. J Pharmacol Exper Therap 1948, 92(4):411-413.
8. Ui M. The multiple biological activities of pertussis toxin. In: Wardlaw AC, Parton R, editors. Pathogenesis and Immunity in Pertussis. New York, John Wiley & Sons, Ltd., 1988: 121-45.
9. Arciniega JL, Corbel M, Dellepiane N, Dobbelaer R, Griffiths E, Heron I, Ivanoff B, Kreeftenberg H, Mastrantonio P, Meade B, Milstein J, Robertson S, Robinson A, Sato H, Sato Y, Schwanig M, Tiru M. WHO guidelines for the production and control of the acellular pertussis component of monovalent or combined vaccines. Biologicals 1998;26(3):195-204.
10. Gillenius P., Jaatmaa E., Askelof P., Granstrom M., Tiru M. The standardization of an assay for pertussis toxin and antitoxin in microplate culture of Chinese hamster ovary cells. J Biol Stand 1985, 13(1):61-66.
11. Kataoka M, Toyoizumi H, Yamamoto A, Ochiai M, Horiuchi Y. Chinese hamster ovary (CHO) cell clustering does not correlate with in vivo histamine-sensitization when measuring residual activity of aldehyde-treated pertussis toxin (PT). Biologicals 2002;30(4):297-302.
12. Munoz JJ, Bergman RI. Bordetella Pertussis. Immunological and Other Biological Activities. New York, Marcel Dekker, Inc., 1977.
13. World Health Organization. Recommendations for whole-cell pertussis vaccine. In: WHO Expert Committee on Biological Standardization. Fifty-sixth Report. Geneva, Switzerland, World Health Organization, 2007: Annex 6 (WHO Technical Report Series No. 941). Available at: http://www.who.int/biologicals/publications/trs/areas/vaccines/whole_cell_pertussis/en/index.html.
14. Pittman M., Cox C.B. Pertussis vaccine testing for freedom-from-toxicity. Appl Microbiol 1965, 13(3):447-456.
15. Pittman M. Determination of the histamine sensitizing unitage of pertussis vaccine. J Biol Stan 1975, 3(2):185-191.
16. Council of Europe. European Pharmacopoeia, 7th ed. Strasbourg, France, European Department for the Quality of Medicines & HealthCare (EDQM), Council of Europe, 2010.
17. Corner GW. A History of the Rockefeller Institute, 1901-1953; Origins and Growth. New York, Rockefeller Institute Press, 1964: 222-3.
18. Hilltop Lab Animals, Inc. Colony History: Hla®(ICR)CVF® [Internet]. [Accessed 4 August 2010.] Available at: http://hilltoplabs.com/public/icrhistory.html.
19. Charles River. Research Animal Models [Internet]. [Accessed 4 August 2010.] Available at: http://www.criver.com/en-US/ProdServ/ByType/ResModOver/ResMod/Pages/SwissWebster(CFW)Mouse.aspx.
20. Hansen CT, Manclark CR, Pittman M, Hinkle WJ. Selective breeding for pertussis HSF sensitivity in the mouse. In: Spiegel A, editor. The Laboratory Animal in Drug Testing. Fifth International Committee on Laboratory Animals Symposium. Stuttgart, Gustav Fischer Verlag, 1973: 151-56.
21. Ma R.Z., Gao J., Meeker N.D., Fillmore P.D., Tung K.S., Watanabe T., Zachary J.R., Offner H., Blankenhorn E.P., Teuscher C. Identification of Bphs, an autoimmune disease locus, as histamine receptor H1. Science. 2002, 297(5581):620-623.
22. Wardlaw A.C. Inheritance of responsiveness to pertussis HSF in mice. Int Arch Allergy 1970, 38(6):573-589.
23. Sudweeks JD, Todd JA, Blankenhorn EP, Wardell BB, Woodward SR, Meeker ND, Estes SS, Teuscher C. Locus controlling Bordetella pertussis-induced histamine sensitization (Bphs), an autoimmune disease-susceptibility gene, maps distal to T-cell receptor β-chain gene on mouse chromosome 6. Proc Natl Acad Sci USA 1993;90(8):3700-4.
24. Meeker N.D., Stafford A.N., Lunceford J.K., Avner P., Ma R.Z., Teuscher C. Physical mapping of the autoimmune disease susceptibility locus Bphs: co-localization with a cluster of genes from the TNF receptor superfamily on mouse chromosome 6. Mamm Genome 1999, 10(9):858-863.
25. Gao J.F., Call S.B., Fillmore P.D., Watanabe T., Meeker N.D., Teuscher C. Analysis of the role of Bphs/Hrh1 in the genetic control of responsiveness to pertussis toxin. Infect Immun 2003, 71(3):1281-1287.
26. Pittman M. Influence of sex of mice on histamine sensitivity and protection against Hemophilus pertussis. J Infect Dis 1951, 89(3):296-299.
27. Preston NW Factors influencing the assay of the histamine-sensitizing factor of Hemophilus pertussis. J Pathol Bacteriol 1959, 78(1):217-224.
28. Miles A.A. Biological standards and the measurement of therapeutic activity. Br Med Bull 1951, 7(4):283-291.
29. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Validation of Analytical Procedures: Text and Methodology Q2(R1). Geneva, Switzerland: ICH, 2005.
30. Xing D., Das R.G., Newland P., Corbel M. Comparison of the bioactivity of reference preparations for assaying Bordetella pertussis toxin activity in vaccines by the histamine sensitisation and Chinese hamster ovary-cell tests: assessment of validity of expression of activity in terms of protein concentration. Vaccine 2002, 20(29-30):3535-3542.
31. World Health Organization. Recommendations for diphtheria, tetanus, pertussis and combined vaccines. In: WHO Expert Committee on Biological Standardization. Fifty-fourth Report. Geneva, Switzerland, World Health Organization, 2005: Annex 5 (WHO Technical Report Series No. 927). Available at: http://www.who.int/biologicals/publications/trs/areas/vaccines/dtp/en/index.html.
32. Horiuchi Y., Takahashi M., Konda T., Ochiai M., Yamamoto A., Kataoka M., Toyoizumi H., Arakawa Y. Quality control of diphtheria tetanus acellular pertussis combined (DTaP) vaccines in Japan. Jpn J Infect Dis 2001, 54(5):167-180.
33. Ishida S., Kurokawa M., Asakawa S., Iwasa S. A sensitive assay method for the histamine-sensitizing factor using change in rectal temperature of mice after histamine challenge as a response. J Biol Stand 1979, 7(1):21-29.
34. Xing D., Maes A., Behr-Gross M.E., Costanzo A., Daas A., Buchheit K.H. Collaborative study for the standardisation of the histamine sensitizing test in mice and the CHO cell-based assay for the residual toxicity testing of acellular pertussis vaccines. Pharmeur Bio Sci Notes 2010, 1:51-63.
35. Ochiai M., Yamamoto A., Kataoka M., Toyoizumi H., Arakawa Y., Horiuchi Y. Highly sensitive histamine-sensitization test for residual activity of pertussis toxin in acellular pertussis vaccine. Biologicals 2007, 35(4):259-264.
36. Gaines-Das R., Ochiai M., Douglas-Bardsley A., Asokanathan C., Horiuchi Y., Rigsby P., Corbel M.J., Xing D.K. Transferability of dermal temperature histamine sensitization test for estimation of pertussis toxin activity in vaccines. Hum Vaccin 2009, 5(3):166-171.
37. Cyr T, Menzies AJ, Calver J, Whitehouse LW. A quantitative analysis for the ADP-ribosylation activity of pertussis toxin: an enzymatic-HPLC coupled assay applicable to formulated whole cell and acellular pertussis vaccine products. Biologicals 2001; 29(2):81-95.
38. Gomez S.R., Yuen C.T., Asokanathan C., Douglas-Bardsley A., Corbel M.J., Coote J.G., Parton R., Xing D.K. ADP-ribosylation activity in pertussis vaccines and its relationship to the in vivo histamine-sensitisation test. Vaccine 2007, 25(17):3311-3318.
39. Yuen C.T., Horiuchi Y., Asokanathan C., Cook S., Douglas-Bardsley A., Ochiai M., Corbel M., Xing D. An in vitro assay system as a potential replacement for the histamine sensitisation test for acellular pertussis based combination vaccines. Vaccine 2010, 28(21):3714-3721.
40. Rappuoli R. New and improved vaccines against diphtheria and tetanus. In: Levine MM, Woodrow GC, Kaper JB, Cobon GS, editors. New Generation Vaccines. New York, Marcel Dekker, Inc., 1997: 417-35.
41. Gomez S.R., Xing D.K., Corbel M.J., Coote J., Parton R., Yuen C.T. Development of a carbohydrate binding assay for the B-oligomer of pertussis toxin and toxoid. Anal Biochem 2006, 356(2):244-253.
42. Bland J.M., Altman D.G. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986, 327(8476):307-310.